129 related articles for article (PubMed ID: 35861410)
1. Correlation of serum vitamin D concentration with humoral-specific IgG2 and IgG4 levels in high responders to immunotherapy with a 300 IR sublingual house dust mite tablet.
Fernandez JC; Luce S; Floch VB; Canonica WG; Batard T; Mascarell L
Clin Exp Allergy; 2022 Oct; 52(10):1219-1224. PubMed ID: 35861410
[No Abstract] [Full Text] [Related]
2. Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy.
Bordas-Le Floch V; Berjont N; Batard T; Varese N; O'Hehir RE; Canonica WG; van Zelm MC; Mascarell L
Allergy; 2022 Apr; 77(4):1263-1273. PubMed ID: 34551124
[TBL] [Abstract][Full Text] [Related]
3. Early increase in serum specific IgG2 upon allergen immunotherapy with a 300 IR sublingual house dust mite tablet.
Berjont N; Floch VVB; O'Hehir RE; Canonica WG; van Zelm MC; Batard T; Mascarell L
Allergy; 2023 Jul; 78(7):2040-2043. PubMed ID: 36809660
[No Abstract] [Full Text] [Related]
4. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of the standardized quality house dust mite sublingual immunotherapy tablet in real life: A noninterventional, open-label study.
Reiber R; Wolf H; Futschik T; Schwab JA; Hölscher U; Schnitker J; Wüstenberg E
J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3221-3223.e5. PubMed ID: 33839345
[No Abstract] [Full Text] [Related]
6. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Demoly P; Kleine-Tebbe J; Rehm D
Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
[TBL] [Abstract][Full Text] [Related]
8. Acute systemic reactions to sublingual immunotherapy for house dust mite.
Janssens NS; van Ouwerkerk L; Gerth van Wijk R; Karim F
Allergy; 2020 Nov; 75(11):2962-2963. PubMed ID: 32449962
[No Abstract] [Full Text] [Related]
9. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet.
Gotoh M; Okubo K; Yuta A; Ogawa Y; Nagakura H; Ueyama S; Ueyama T; Kawashima K; Yamamoto M; Fujieda S; Sakashita M; Sakamoto H; Iwasaki N; Mori E; Endo T; Ohta N; Kitazawa H; Okano M; Asako M; Takada M; Terada T; Inaka Y; Yonekura S; Matsuoka T; Kaneko S; Hata H; Hijikata N; Tanaka H; Masuyama K; Okamoto Y
Allergol Int; 2020 Jan; 69(1):104-110. PubMed ID: 31421989
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy with house dust mite tablets in children-The evidence-based journey of allergen immunotherapy proceeds.
Pfaar O
Allergy; 2018 Dec; 73(12):2271-2273. PubMed ID: 30113079
[No Abstract] [Full Text] [Related]
11. The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation.
Kito H; Du W; Nakazawa H; Lund K; Ohashi-Doi K
Biol Pharm Bull; 2019; 42(6):1030-1033. PubMed ID: 31155578
[TBL] [Abstract][Full Text] [Related]
12. Improvements with sublingual house dust mite immunotherapy in allergic rhinitis.
Lipworth B
J Allergy Clin Immunol; 2016 Aug; 138(2):634-5. PubMed ID: 27233152
[No Abstract] [Full Text] [Related]
13. Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis.
Liao W; Hu Q; Shen LL; Hu Y; Tao HF; Li HF; Fan WT
Medicine (Baltimore); 2015 Jun; 94(24):e701. PubMed ID: 26091451
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.
Ohashi-Doi K; Kito H; Du W; Nakazawa H; Ipsen H; Gudmann P; Lund K
Int Arch Allergy Immunol; 2017; 174(1):26-34. PubMed ID: 28950271
[TBL] [Abstract][Full Text] [Related]
15. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial.
Demoly P; Corren J; Creticos P; De Blay F; Gevaert P; Hellings P; Kowal K; Le Gall M; Nenasheva N; Passalacqua G; Pfaar O; Tortajada-Girbés M; Vidal C; Worm M; Casale TB
J Allergy Clin Immunol; 2021 Mar; 147(3):1020-1030.e10. PubMed ID: 32890575
[TBL] [Abstract][Full Text] [Related]
16. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
17. Sublingual immunotherapy (SLIT) for house dust mite - when to take a break?: An unusual reaction to SLIT post vaccinations.
Gallagher A; Trujillo J
Ann Allergy Asthma Immunol; 2023 Jun; 130(6):809-810. PubMed ID: 36924938
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
19. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients.
Bozek A; Starczewska-Dymek L; Jarzab J
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):77-82. PubMed ID: 28668244
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of the 300 IR sublingual house dust mite allergen immunotherapy tablet: 2-year interim analysis of a specified drug-use survey.
Okamoto Y; Ishii K; Kato M; Hayashi H; Hata T
Immunotherapy; 2021 Nov; 13(16):1333-1343. PubMed ID: 34617449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
